Literature DB >> 32561103

Surgical oncology in patients aged 80 years and older is associated with increased postoperative morbidity and mortality: A systematic review and meta-analysis of literature over 25 years.

V Lopez-Lopez1, A J Gómez-Ruiz2, D Eshmuminov3, P A Cascales-Campos1, F Alconchel1, J Arevalo-Perez4, R Robles Campos1, P Parrilla Paricio1.   

Abstract

BACKGROUND: The study aim is to analyze the evolution over the last 25 years of the results reported after abdominal oncological surgery in patients aged 80 years of age and older. The primary endpoint was morbidity and mortality in this group of patients; the secondary endpoint was overall survival.
METHODS: A systematic search strategy was used to browse through Medline/PubMed, EMBASE, Scopus, ClinicalTrials.gov, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials using a combination of standardized index terms. Studies published between 1997 and 2017 were selected. Only those studies that showed morbidity and mortality after digestive and hepatobiliary tract oncological surgery in individuals aged 80 years and older were included. The PROSPERO registration number is CRD42018087921. PRISMA and MOOSE guidelines were applied.
RESULTS: A total of 79 studies were included, categorized by origin of malignancy: esophageal (7), stomach (26), liver (4), pancreas (19), and colorectal (23). Compared with the non-elderly group, the elderly group had similar esophageal morbidity with higher mortality (RR 2.51, 1.50 to 4.21; P = 0.0005); higher gastric morbidity (RR 1.25, 1.09 to 1.43; P = 0.001), and mortality (RR 2.51, 1.81 to 3.49; P = 0.0001); similar liver morbidity and mortality; higher pancreatic morbidity (RR 1.17, 1.03 to 1.33; P = 0.02) and mortality (RR 2.37, 1.86 to 3.03; P < 0.00001); and similar colorectal morbidity with higher mortality (RR 4.44, 1.91 to 10.32; P = 0.005).
CONCLUSION: Oncological surgery of most abdominal visceral tumors is associated with increased morbidity and mortality in patients older than 80 years.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aged 80; Elderly; Surgery

Mesh:

Year:  2019        PMID: 32561103     DOI: 10.1016/j.suronc.2019.12.007

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  5 in total

1.  Short- and Long-term Outcome After Gastric Cancer Resection in Patients Aged 80 Years and Older.

Authors:  Shintaro Hashimoto; Masato Araki; Yorihisa Sumida; Kouki Wakata; Kiyoaki Hamada; Tota Kugiyama; Ayako Shibuya; Masato Nishimuta; Akihiro Nakamura
Journal:  Cancer Diagn Progn       Date:  2022-03-03

2.  N6-methyladenosine methyltransferase KIAA1429 elevates colorectal cancer aerobic glycolysis via HK2-dependent manner.

Authors:  Ying Li; Liang He; Yingkai Wang; Yan Tan; Fan Zhang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Transanal Endoscopic Microsurgery (TEMS) for Rectal Cancer: Patient Decision-making, Postoperative Experience and Quality of Life.

Authors:  Alexandra Koreli; George Briassoulis; Michail Sideris; Anastas Philalithis; Savvas Papagrigoriadis
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

4.  Outcomes of curative esophageal cancer surgery in elderly: A meta-analysis.

Authors:  Nikolaj S Baranov; Cettela Slootmans; Frans van Workum; Bastiaan R Klarenbeek; Yvonne Schoon; Camiel Rosman
Journal:  World J Gastrointest Oncol       Date:  2021-02-15

5.  Feasibility of a prehabilitation programme dedicated to older patients with cancer before complex medical-surgical procedures: the PROADAPT pilot study protocol.

Authors:  Mélanie Roche; Christine Ravot; Amélie Malapert; Sophie Paget-Bailly; Charlène Garandeau; Virginie Pitiot; Mélanie Tomatis; Benjamin Riche; Béatrice Galamand; Marion Granger; Claire Barbavara; Chrystelle Bourgeois; Evelyne Genest; Laetitia Stefani; Max Haïne; Elisabeth Castel-Kremer; Isabelle Morel-Soldner; Vincent Collange; Olivia Le Saux; David Dayde; Claire Falandry
Journal:  BMJ Open       Date:  2021-04-02       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.